Drug Profile
Arylsulfatase B controlled release - Hanmi Pharmaceutical
Alternative Names: HM 15450Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Arylsulfatases; Enzymes
- Mechanism of Action Arylsulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mucopolysaccharidosis VI
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-VI in South Korea (Parenteral, Controlled release)
- 08 Dec 2021 HM 15450 is still in preclinical development for Mucopolysaccharidosis VI in South Korea (Hanmi Pharmaceutical pipeline, December 2021)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-VI in South Korea (Parenteral, Controlled release)